Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Prism Research

Neither a doctor nor a teaching hospital

Research payments

$3,082,944

435 payments

Through program year 2023, Prism Research is reported as receiving $3,082,944 in research payments, across 435 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $85,051 18
2022 Research $450,772 81
2021 Research $2,191,085 266
2020 Research $223,667 37
2019 Research $132,369 33

Breakdown

Who paid Research payments · program years 2019–2023
  1. Pfizer Inc. $2,057,000 63 payments
  2. Incyte Corporation $507,958 62 payments
  3. Merck Sharp & Dohme Corporation $387,361 36 payments
  4. AbbVie, Inc. $109,681 25 payments
  5. Kowa Research Institute, Inc. $8,500 1 payment
  6. Zogenix Inc. $6,188 3 payments
  7. Sunovion Pharmaceuticals Inc. $5,953 240 payments
  8. Sumitomo Pharma America, Inc. $304 5 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 1 Randomized Openlabel Crossover Singledose Study to Evaluate the Bioequivalence of Candidate Capsule Formulations of Pf06651600 to Tablets and Estimate the Effect of Highfat Meal on Bioavailability in Healthy Participants $1,317,512 16 payments
  2. A Randomized Doubleblind Sponsoropen Placebocontrolled Dose Escalation Study to Evaluate the Safety Tolerability and Pharmacokinetics of Pf07209326 in Healthy Participants $446,698 14 payments
  3. Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants with End-Stage Renal Disease on Hemodialysis $375,847 26 payments
  4. A Phase 1 Nonrandomized Open Label Single Dose Study to Evaluate the Pharmacokinetics Safety and Tolerability of Pf06700841 in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function $269,102 24 payments
  5. A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Renal Function and Participants With Renal Impairment $263,264 30 payments
  6. A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis $159,946 19 payments
  7. A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis $55,428 10 payments
  8. M14-702 $41,929 14 payments
  9. M18-918 $37,104 5 payments
  10. M14-397 $30,649 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record